Synergy between colistin and the signal peptidase inhibitor MD3 is dependent on the mechanism of colistin resistance in Acinetobacter baumannii

7Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Synergy between colistin and the signal peptidase inhibitor MD3 was tested against isogenic mutants and clinical pairs of Acinetobacter baumannii isolates. Checkerboard assays and growth curves showed synergy against both colistin-susceptible strains (fractional inhibitory concentration index [FICindex] = 0.13 to 0.24) and colistin-resistant strains with mutations in pmrB and phosphoethanolamine modification of lipid A (FICindex = 0.14 to 0.25) but not against colistin-resistant Δlpx strains with loss of lipopolysaccharide (FICindex = 0.75 to 1). A colistin/MD3 combination would need to be targeted to strains with specific colistin resistance mechanisms.

Cite

CITATION STYLE

APA

Martínez-Guitián, M., Vázquez-Ucha, J. C., Odingo, J., Parish, T., Poza, M., Waite, R. D., … Beceiro, A. (2016). Synergy between colistin and the signal peptidase inhibitor MD3 is dependent on the mechanism of colistin resistance in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 60(7), 4375–4379. https://doi.org/10.1128/AAC.00510-16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free